Rate My Professor Andy Woods

Woods' research focuses on pharmacy practice, particularly in pharmacotherapy for respiratory conditions, drug-induced adverse effects, and educational innovations. Key publications include "Corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease" (2014, International Journal of Chronic Obstructive Pulmonary Disease, cited 147 times), "Impact of distance education via interactive videoconferencing on students’ course performance and satisfaction" (2018, Advances in Physiology Education, cited 53 times), "Cannabinoid hyperemesis syndrome: an emerging drug-induced disease" (2016, American Journal of Therapeutics, cited 33 times), "Low-dose naloxone for prophylaxis of postoperative nausea and vomiting: a systematic review and meta-analysis" (2017, Pharmacotherapy, cited 31 times), and "Strategies to preserve the use of statins in patients with previous muscular adverse effects" (2012, American Journal of Health-System Pharmacy, cited 31 times). Additional works cover aclidinium bromide for COPD management (2013), ceftolozane/tazobactam for multidrug-resistant infections (2018), and evidence-based nebulization during the SARS-CoV-2 pandemic (2021). Woods participated in the American Association of Colleges of Pharmacy Academic Leadership Fellows Program, enhancing his contributions to pharmacy education and clinical practice.